Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.

OBJECTIVE The purpose of this study was to determine the response of ovarian carcinoma cells to TGF-beta1 and to examine components of the TGF-beta signaling pathway. METHODS Twenty-three primary ovarian cancer cell (CSOC) cultures established from solid ovarian carcinomas were treated with TGF-beta1 and assayed for growth response by MTT assay. Expression of TGF-beta receptor I (TbetaR-I) and receptor II (TbetaR-II), essential for effective signaling, was determined by Western analysis of CSOC cultures. TGF-beta1 ligand-induced phosphorylation of TbetaR-I was determined by immunoprecipitation of TbetaR-I followed by a protein kinase assay to assess TbetaR-I phosphorylation, an essential first step in TGF-beta signal transduction. Gelatin zymography performed on 5 CSOC cultures incubated with TGF-beta1 was used to determine TGF-beta's effect on matrix metalloproteinase production. Normal ovarian surface epithelial cells were used for comparison. RESULTS Eighteen of twenty-three (78%) CSOC cultures demonstrated no significant growth inhibition in response to TGF-beta1 treatment. All cell cultures expressed TbetaR-I and TbetaR-II and exhibited TbetaR-I phosphorylation following TGF-beta1 treatment. CSOC cultures produced significantly higher levels of matrix metalloproteinase-2 (MMP-2) than normal ovarian surface epithelial cells; however, the level of MMP-2 expression was not regulated by TGF-beta1. CONCLUSION These results indicate that TGF-beta1 resistance and higher levels of MMP-2 production may be inherent properties of the ovarian cancer phenotype. The initial steps in the TGF-beta signaling pathway, receptor expression, ligand binding, and TbetaR-I phosphorylation, appear to be functional in primary ovarian cancer cell cultures. Therefore, the mechanism of growth resistance is downstream of TbetaR-I phosphorylation.

[1]  A. Brunner,et al.  Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells , 1987, Molecular and cellular biology.

[2]  J. Massagué,et al.  Complementation between kinase‐defective and activation‐defective TGF‐beta receptors reveals a novel form of receptor cooperativity essential for signaling. , 1996, The EMBO journal.

[3]  S. Saga,et al.  Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. , 1996, Cancer research.

[4]  T. Thompson,et al.  Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. , 1996, Cancer research.

[5]  R. Eckert,et al.  Transforming Growth Factor β1 Regulation of Metalloproteinase Production in Cultured Human Cervical Epithelial Cells , 1994 .

[6]  T. L. Moser,et al.  Secretion of extracellular matrix‐degrading proteinases is increased in epithelial ovarian carcinoma , 1994, International journal of cancer.

[7]  K. M. Mulder,et al.  Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. , 1989, Experimental cell research.

[8]  T. Hurskainen,et al.  Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[9]  Keunchil Park,et al.  Expression of Transforming Growth Factor β Type II Receptor Reduces Tumorigenicity in Human Gastric Cancer Cells , 1997 .

[10]  J. Harb,et al.  Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumor but not from metastases. , 1996, Cancer research.

[11]  J. Massagué,et al.  Betaglycan presents ligand to the TGFβ signaling receptor , 1993, Cell.

[12]  G. Sutton,et al.  Collagenase expression in ovarian cancer cell lines. , 1995, Gynecologic oncology.

[13]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[14]  B. Karlan,et al.  Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. , 1995, American journal of obstetrics and gynecology.

[15]  J. Massagué,et al.  Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin , 1994, Molecular and cellular biology.

[16]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[17]  R. Bast,et al.  Transforming growth factor‐beta inhibits proliferation of human ovarian cancer cells obtained from ascites , 1994, Cancer.

[18]  Luzhe Sun,et al.  Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells (*) , 1995, The Journal of Biological Chemistry.

[19]  Y. Bang,et al.  Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. , 1997, Cancer research.

[20]  R. L. Baldwin,et al.  Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. , 1995, Gynecologic oncology.

[21]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[22]  E. Barrack,et al.  Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. , 1995, Cancer research.

[23]  T. Crowe,et al.  Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. , 1998, Cancer research.

[24]  R. Bast,et al.  Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. , 1996, Gynecologic oncology.

[25]  L. Matrisian.  The matrix‐degrading metalloproteinases , 1992, Journal of neuro-oncology.

[26]  L. Myeroff,et al.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. , 1998, Cancer research.

[27]  R. L. Baldwin,et al.  Altered expression of transforming growth factor‐β ligands and receptors in primary and recurrent ovarian carcinoma , 1999, Cancer.

[28]  J. Wrana,et al.  Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. , 1989, The Journal of biological chemistry.

[29]  R Wieser,et al.  Mechanism of activation of the TGF-beta receptor. , 1994, Nature.

[30]  Jeffrey L. Wrana,et al.  Mechanism of activation of the TGF-β receptor , 1994, Nature.

[31]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[32]  A. Tamakoshi,et al.  Characterization of extracellular matrix‐degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form , 1995, Cancer.

[33]  R. Bast,et al.  Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. , 1995, Cancer research.

[34]  R. Smith.  The anti-proliferative action of transforming growth factor-beta 1 on a rat intestinal epithelial cell line (RIE-1) is dependent on cell population density and culture passage number. , 1994, The International journal of biochemistry.

[35]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.